Novo Nordisk's Chinese Filing and a 30 Million-Share Buyback: A Stock Caught Between Two Narratives

Novo Nordisk buys back shares amid Deutsche Bank downgrade; China accepts oral Wegovy filing, a key catalyst for growth.

The Danish pharmaceutical giant is sending investors a mixed message these days. Management has been steadily repurchasing its own shares at a pace that signals quiet confidence, while at least one major bank has turned openly bearish on the stock's prospects. Meanwhile, a regulatory filing in Beijing could reshape the company's growth trajectory in the world's second-largest pharmaceutical market.

At the heart of the tension is a simple question: can Novo Nordisk translate its oral Wegovy pill into a meaningful competitive advantage against Eli Lilly, or is the market right to remain skeptical?

A Buyback That Speaks Volumes

Since launching its repurchase program on February 4, Novo Nordisk has acquired nearly 30 million of its own B-shares at an average price of 280.34 Danish kroner, representing a total transaction value of roughly 8.4 billion kroner. The most recent tranche, purchased during a single trading week starting August 17, amounted to just over one million shares.

The timing is notable. Deutsche Bank Research downgraded the stock from Hold to Sell on August 25, slashing its price target from 290 to 265 Danish kroner on growth concerns. JPMorgan, for its part, raised its target to 275 kroner the same day but kept a Neutral rating. Neither bank is recommending investors buy the stock, and the management's ongoing buybacks stand in stark contrast to that skepticism.

The stock closed Friday at 39.41 euros, roughly 28 percent below its 52-week high of 54.86 euros, with the past week's decline a modest 2.0 percent. The muted reaction suggests neither the Chinese news nor the Deutsche Bank downgrade has yet triggered a significant repricing.

The China Catalyst

The most consequential development sits in Peking, where China's drug regulator has accepted Novo Nordisk's application for the oral version of Wegovy. This is not an approval — merely the formal initiation of a review process — but the potential prize is enormous. China represents one of the largest untapped markets for obesity treatments globally, and access there could help offset the competitive pressure Novo Nordisk faces from Eli Lilly in the GLP-1 segment.

The company is also pushing forward on the clinical front. On August 12, a late-stage study began testing lower doses of the Wegovy tablet across 62 sites in the US and Europe, enrolling 450 participants. The OASIS-5 trial aims to identify the lowest effective maintenance dose, which could improve both tolerability and cost efficiency over the long term.

Mixed Signals From the Pipeline

Elsewhere in the development portfolio, there are signs of progress. Lexicon Pharmaceuticals received a third milestone payment of $10 million from Novo Nordisk under their joint obesity program — an indication of forward momentum, though details on the specific development step were not disclosed.

But operational friction remains. Scholar Rock withdrew a European regulatory application last week following issues at a Novo Nordisk-operated manufacturing facility in Bloomington, Indiana, putting the company's production capacity under renewed scrutiny. The FDA also approved Eli Lilly's Mounjaro on Friday for reducing heart attack and stroke risk in Type 2 diabetes patients with high cardiovascular risk — an indication expansion that intensifies the competitive landscape further.

Two Paths Forward

The stock currently trades at 39.23 euros, roughly 30 percent above its early March low but still below its 50-day moving average of 41.79 euros. The RSI sits at 42.5, indicating neither oversold nor overbought conditions — a technical picture that mirrors the fundamental ambiguity.

The company's August guidance revision offers some support: adjusted revenue growth at constant exchange rates is now projected between 0 and minus 6 percent for fiscal 2026, improved from the previous range of minus 4 to minus 12 percent. Adjusted operating profit guidance was similarly raised. In the second quarter, adjusted revenue rose 7 percent and adjusted operating profit climbed 11 percent, both at constant exchange rates.

The bull case rests on two pillars: a swift Chinese approval process and positive OASIS-5 data confirming a lower, better-tolerated maintenance dose. Success on both fronts could close the valuation gap to historical highs. The bear case, articulated by Deutsche Bank, sees growth concerns persisting, with the stock likely to remain below its 50-day average if the Chinese review stalls or the dose-finding study disappoints.

The Chinese regulatory timeline remains unspecified, making the progress of the Wegovy review and interim OASIS-5 results the key catalysts for the coming months. For now, investors are left weighing management's buyback conviction against a skeptical analyst community — with the Chinese filing potentially tipping the scales in either direction.